Recombinant Human BAFF protein

BAFF (B cell-activating factor), also known as TNF superfamily member 13B (TNFSF13B), is a critical cytokine involved in B cell survival, proliferation, and differentiation. It binds to three receptors: BAFF-R, TACI, and BCMA, which are expressed on B cells and plasma cells. Discovered in 1999. BAFF plays a central role in maintaining B cell homeostasis and adaptive immunity. Dysregulation of BAFF signaling is linked to autoimmune diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis) and B cell malignancies, making it a key therapeutic target.

Recombinant BAFF protein is produced using genetic engineering techniques, typically in mammalian expression systems (e.g., CHO or HEK293 cells) to ensure proper post-translational modifications and functional activity. This engineered protein retains the native trimeric structure required for receptor binding and biological function. Its production enables controlled in vitro and in vivo studies of B cell biology, immune regulation, and disease mechanisms.

In research, recombinant BAFF is widely used to investigate B cell development, antibody production, and pathological processes in autoimmune disorders. It also serves as a tool for screening BAFF inhibitors, such as belimumab—the first FDA-approved anti-BAFF monoclonal antibody for lupus treatment. Additionally, it has potential applications in vaccine development by enhancing B cell responses. As a standardized reagent, recombinant BAFF ensures reproducibility in studies exploring immune modulation, drug discovery, and therapeutic interventions targeting the BAFF/APRIL signaling axis. Its availability accelerates both basic research and translational efforts in immunology and immunotherapy.